Efficacy and Safety of Tavapadon, an Orally Administered, Once-daily, Selective D1/D5 Partial Dopamine Agonist, Adjunctive to Levodopa for Treatment of Parkinson’s Disease with Motor Fluctuations (S37.003)
To evaluate the efficacy, safety, and tolerability of tavapadon adjunctive to levodopa in adults with Parkinson’s disease (PD) and motor fluctuations.
Authors
- Daniel Kremens
- Gina Pastino (ORCID: https://orcid.org/0000-0002-6474-5787)
- Nicole Golonski
- E. Koenig
- Ariane Park (ORCID: https://orcid.org/0000-0002-3826-6694)
- Raymond Sanchez
- Lawrence Elmer
- Steven Tringali (ORCID: https://orcid.org/0000-0001-5999-0027)
- Cari Combs
- Ih Chang (ORCID: https://orcid.org/0000-0002-4123-1636)
- Stuart Isaacson (ORCID: https://orcid.org/0000-0002-9914-5706)
- Sridhar Duvvuri
- Robert A. Hauser (ORCID: https://orcid.org/0000-0002-6369-1203)
- William G. Ondo (ORCID: https://orcid.org/0000-0001-6090-4261)
- Pinky Agarwal (ORCID: https://orcid.org/0000-0002-1219-1735)
- Hubert H. Fernandez (ORCID: https://orcid.org/0000-0002-8553-5316)
- Matthew Leoni
Institutions
- Houston Methodist (US)
- Cleveland Clinic (US)
- Thomas Jefferson University (US)
- The Ohio State University Wexner Medical Center (US)
- Cerevel Therapeutics (United States) (US)
- Evergreen Health Medical Center (US)
- University of Toledo (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208468
- Citations
- 2
- Primary Topic
- Neurological disorders and treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.78